Literature DB >> 8687191

Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.

R A Weeks1, P Piccini, A E Harding, D J Brooks.   

Abstract

We have investigated striatal dopamine D1 and D2 receptor binding in asymptomatic subjects from Huntington's disease (HD) families using positron emission tomography. Nineteen adult subjects at risk of developing HD were scanned with 11C-SCH 23390 and 11C-raclopride to calculate the D1 and D2 receptor binding potential, respectively. Eight of the 19 were shown to have the HD mutation; of these, 4 subjects had significant reductions in striatal dopamine receptor binding. Abnormalities were more common in older subjects and were not correlated with the size of the HD mutation. There was a strong coefficient of correlation between individual levels of striatal D1 and D2 binding in subjects with the mutation. Of 6 other cases with a 50% risk of carrying the HD gene, 1 showed subclinical loss of caudate and putamen D2 binding. Our study suggests that both striatal D1 and D2 dopamine receptors are lost in parallel from both caudate and putamen in presymptomatic HD and that dopamine receptor binding provides a sensitive means of detecting subclinical striatal dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687191     DOI: 10.1002/ana.410400110

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  42 in total

1.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

Authors:  S W Davies; M Turmaine; B A Cozens; A S Raza; A Mahal; L Mangiarini; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

Authors:  J H Cha; A S Frey; S A Alsdorf; J A Kerner; C M Kosinski; L Mangiarini; J B Penney; S W Davies; G P Bates; A B Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

4.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

Review 5.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

Review 6.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

Review 7.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

Review 8.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

9.  Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.

Authors:  D S Reynolds; R J Carter; A J Morton
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

10.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.